Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LARIN FE 1/20 vs DESOGEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.
Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.
Prevention of pregnancy in women who elect to use an oral contraceptive
Prevention of pregnancy,Treatment of moderate acne vulgaris in females at least 15 years old who have no known contraindications, have achieved menarche, and are unresponsive to topical therapy,Treatment of heavy menstrual bleeding (off-label)
One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.
One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.
Ethinyl estradiol: ~13 hours (range 7-20); norethindrone: ~8-11 hours. Steady-state reached in 5-7 days.
The terminal elimination half-life of etonogestrel is approximately 30-41 hours. This long half-life supports once-daily dosing for contraceptive efficacy.
Ethinyl estradiol is metabolized primarily via CYP3A4, with sulfation and glucuronidation. Norethindrone is reduced and conjugated, primarily via CYP3A4 and other CYP450 enzymes.
Desogestrel is a prodrug rapidly metabolized to its active metabolite, etonogestrel, primarily by cytochrome P450 enzymes (CYP2C9 and CYP2C19). Ethinyl estradiol is metabolized by CYP3A4 and undergoes glucuronidation.
Renal (60% as metabolites, <10% unchanged); biliary/fecal (40%)
Desogestrel is primarily metabolized to its active metabolite etonogestrel, which is extensively metabolized and excreted as conjugates. About 50-60% is excreted via urine and 30-40% via feces. Less than 1% is excreted unchanged.
Ethinyl estradiol: 97-98% (albumin, SHBG); norethindrone: 80-85% (albumin, SHBG)
Etonogestrel is 95-98% bound to plasma proteins, primarily albumin and sex hormone-binding globulin (SHBG). Desogestrel itself is about 80% bound to albumin.
Ethinyl estradiol: 2.5-5 L/kg; norethindrone: 2-4 L/kg. Indicates extensive tissue distribution.
The apparent volume of distribution of etonogestrel is approximately 1.3-1.6 L/kg. This relatively large Vd indicates extensive tissue distribution.
Oral: ~40% for ethinyl estradiol (first-pass metabolism); ~64% for norethindrone (range 50-75%)
Oral bioavailability of desogestrel is essentially complete due to rapid and extensive metabolism to etonogestrel. The absolute bioavailability of etonogestrel after oral desogestrel is about 76-80%.
No dose adjustment required for mild to moderate renal impairment. Severe renal impairment (GFR <30 m L/min) may require monitoring due to potential fluid retention; use lowest effective dose.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment (Cr Cl <30 m L/min) due to potential estrogen accumulation.
Contraindicated in Child-Pugh class C cirrhosis. For Child-Pugh class B, use with caution and only if benefits outweigh risks; consider alternative methods of contraception. Child-Pugh class A: no adjustment necessary.
Contraindicated in Child-Pugh class B and C (moderate to severe hepatic impairment). Use with caution in Child-Pugh class A; monitor liver function.
Approved for post-menarcheal adolescents. Same dosing as adults: one active tablet daily for 21 days, then placebo for 7 days. Weight-based adjustments not required.
Only after menarche. Same dosing as adults: one tablet daily for 21 days, then 7 days off. No weight-based dosing; use standard adult dose.
Not indicated for postmenopausal women. No specific geriatric dose adjustments, but consider increased risk of thrombotic events and manage cardiovascular risk factors.
Not indicated for use after menopause. For perimenopausal women, same adult dosing applies; monitor for increased thromboembolic risk.
Cigarette smoking increases the risk of serious cardiovascular side effects from oral contraceptive use. The risk increases with age and with heavy smoking (≥15 cigarettes per day) and is quite marked in women >35 years of age. Women who use oral contraceptives should be strongly advised not to smoke.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptives. Risk increases with age (especially >35 years) and number of cigarettes smoked. Women who use COCs should be strongly advised not to smoke.
Thrombotic disorders: Risk of venous thromboembolism, arterial thrombosis, stroke, myocardial infarction.,Hepatic disease: Discontinue if jaundice or cholestasis develops.,Hypertension: Monitor blood pressure; may cause new-onset or worsening hypertension.,Gallbladder disease: Increased risk of gallstones.,Carbohydrate metabolism: May impair glucose tolerance.,Hypertriglyceridemia: May cause pancreatitis if elevated.,Uterine bleeding: Discontinue if unexplained amenorrhea or irregular bleeding persists.,Ocular disorders: Retinal thrombosis; discontinue if sudden partial or complete vision loss.,Depression: May recur or worsen.,Toxic shock syndrome: Associated with use of vaginal rings, but not specifically with this pill.
Increased risk of thromboembolic disorders (e.g., stroke, MI, DVT, PE),Increased risk of cervical cancer and hepatocellular carcinoma,Elevated blood pressure,Gallbladder disease,Carbohydrate and lipid metabolism effects,Headache, including migraine,Altered menstrual bleeding patterns,Depression,Contact lens intolerance,Hereditary angioedema,Chloasma,Hepatic impairment,Pregnancy (discontinue if pregnancy occurs),Lactation (may decrease milk production)
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast carcinoma,Endometrial carcinoma or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Pregnancy (known or suspected),Benign or malignant liver tumors (current or history),Active liver disease (e.g., acute hepatitis, decompensated cirrhosis),Hypersensitivity to any component of the product
Hypersensitivity to any component,Thrombophlebitis or thromboembolic disorder (current or history),Cerebrovascular or coronary artery disease,Known or suspected carcinoma of the breast,Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Benign or malignant liver tumor (current or history),Severe hepatic impairment (e.g., acute liver disease, decompensated cirrhosis),Active viral hepatitis,Uncontrolled hypertension,Diabetes mellitus with vascular involvement,Headaches with focal neurological symptoms (e.g., migraine with aura) in women >35 years,Major surgery with prolonged immobilization,Smoking in women >35 years
No significant food interactions. However, grapefruit juice may slightly increase ethinyl estradiol levels; avoid large amounts. The ferrous fumarate in placebo pills may cause gastrointestinal upset; take with food if needed.
No significant food interactions. Grapefruit juice may increase estrogen levels via CYP3A4 inhibition, but clinical relevance is minimal. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
Pregnancy category X. Use contraindicated in pregnancy due to known teratogenicity. First-trimester exposure associated with cardiovascular defects and limb reduction defects. Second and third trimesters: no increased risk of malformations but potential for adverse effects from progestational agents and estrogen. Risk of fetal genital abnormalities with prolonged exposure.
Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal death, jaundice, and neurodevelopmental issues. Contraindicated in pregnancy.
Contraindicated in breastfeeding. Small amounts of estrogen and progestin (norethindrone) pass into breast milk. M/P ratio: not established for this combination. May reduce milk production and quality. Use alternative contraception if breastfeeding.
Excreted in breast milk; M/P ratio not well-defined. May reduce milk production and quality. Use is generally not recommended during breastfeeding due to potential adverse effects on the infant.
Contraindicated in pregnancy; no dose adjustments recommended as use is prohibited. No pharmacokinetic studies during pregnancy due to contraindication.
Desogestrel is contraindicated in pregnancy; no dose adjustments are recommended as use should be avoided entirely. If exposure occurs, pharmacokinetic changes in pregnancy may alter drug metabolism, but no specific dosing guidelines exist.
LARIN FE 1/20 is a combination oral contraceptive containing norethindrone acetate (1 mg) and ethinyl estradiol (20 mcg). It uses a 24/4 regimen with 24 active pills and 4 ferrous fumarate placebo pills. The iron supplements in the placebo pills help reduce the risk of iron deficiency anemia. Advise patients that spotting or breakthrough bleeding is common in the first few cycles. Monitor for hypertension, migraines, and thrombotic events. Smoking increases cardiovascular risk, especially in women over 35. LARIN FE 1/20 may decrease milk production in breastfeeding women.
Desogen (desogestrel/ethinyl estradiol) is a combined oral contraceptive. For patients with a history of venous thromboembolism, avoid use. Consider progestin-only alternative if contraindication to estrogen exists. Counsel on increased risk of breakthrough bleeding with missed doses. Monitor blood pressure at baseline and annually.
Take one pill daily at the same time each day. Swallow the pill whole; do not crush or chew.,Start the pack on the first Sunday after your period starts (unless instructed otherwise).,Use backup contraception (like condoms) for the first 7 days if you start taking the pill for the first time.,If you miss a pill, refer to the package insert for instructions. Missing pills increases pregnancy risk.,Common side effects include nausea, breast tenderness, and breakthrough bleeding. These often improve after a few months.,Contact your healthcare provider if you experience severe abdominal pain, chest pain, sudden shortness of breath, severe headaches, vision changes, or leg pain/swelling (possible blood clots).,Talk to your doctor before starting if you smoke, are over 35, have high blood pressure, migraines with aura, or a history of blood clots.,The iron pills (brown tablets) are not active birth control; they are taken during the fourth week to help prevent anemia.,Do not stop taking the pill without consulting your doctor.
Take one tablet daily at the same time to maintain hormone levels.,If a dose is missed, follow package instructions; use backup contraception if needed.,Report symptoms of blood clots: leg pain/swelling, chest pain, sudden shortness of breath.,Avoid smoking, especially if over 35, due to increased cardiovascular risk.,May cause nausea, breast tenderness, or mood changes; usually resolves within 3 cycles.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LARIN FE 1/20 vs DESOGEN, answered by our medical review team.
LARIN FE 1/20 is a Combination Oral Contraceptive that works by LARIN FE 1/20 is a combination oral contraceptive containing ethinyl estradiol and norethindrone. It inhibits ovulation by suppressing gonadotropin release (FSH and LH) from the pituitary, increases viscosity of cervical mucus, and alters endometrial receptivity.. DESOGEN is a Combination Oral Contraceptive that works by Progestin (desogestrel) combined with ethinyl estradiol inhibits gonadotropin release, suppressing ovulation. Also increases cervical mucus viscosity, impeding sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LARIN FE 1/20 and DESOGEN depend on the specific clinical indication. These are both Combination Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LARIN FE 1/20 is: One tablet orally once daily for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets per cycle.. The standard adult dose of DESOGEN is: One tablet (0.15 mg desogestrel and 0.03 mg ethinyl estradiol) orally once daily for 21 consecutive days, followed by 7 hormone-free days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LARIN FE 1/20 and DESOGEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LARIN FE 1/20 is classified as Category C. Pregnancy category X. Use contraindicated in pregnancy due to known teratogenicity. First-trimester exposure associated with cardiovascular defects and limb reduction defects. Seco. DESOGEN is classified as Category C. Pregnancy category X. First trimester: Known risk of fetal harm, including cardiovascular defects and limb reduction defects. Second and third trimesters: Increased risk of fetal d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.